Literature DB >> 14673054

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

Bruce D Cheson1, John M Bennett, Kenneth J Kopecky, Thomas Büchner, Cheryl L Willman, Elihu H Estey, Charles A Schiffer, Hartmut Doehner, Martin S Tallman, T Andrew Lister, Francesco Lo-Coco, Roel Willemze, Andrea Biondi, Wolfgang Hiddemann, Richard A Larson, Bob Löwenberg, Miguel A Sanz, David R Head, Ryuzo Ohno, Clara D Bloomfield, Francesco LoCocco.   

Abstract

An International Working Group met to revise the diagnostic and response criteria for acute myelogenous leukemia originally published in 1990, as well as to provide definitions of outcomes and reporting standards to improve interpretability of data and comparisons among trials. Since the original publication, there have been major advances in our understanding of the biology and molecular genetics of acute leukemia that are clinically relevant and warrant incorporation into response definitions. Differences from the 1990 recommendations included a category of leukemia-free state, new criteria for complete remission, including cytogenetic and molecular remissions and remission duration. Storage of viable blasts for correlative studies is important for future progress in the therapy of these disorders.

Entities:  

Mesh:

Year:  2003        PMID: 14673054     DOI: 10.1200/JCO.2003.04.036

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  940 in total

1.  A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia.

Authors:  Tapan M Kadia; Hui Yang; Alessandra Ferrajoli; Sirisha Maddipotti; Claudia Schroeder; Timothy L Madden; Julianne L Holleran; Merrill J Egorin; Farhad Ravandi; Deborah A Thomas; Willie Newsome; Blanca Sanchez-Gonzalez; James A Zwiebel; Igor Espinoza-Delgado; Hagop M Kantarjian; Guillermo Garcia-Manero
Journal:  Br J Haematol       Date:  2010-04-29       Impact factor: 6.998

2.  Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy.

Authors:  Farhad Ravandi; Jorge Cortes; Stefan Faderl; Susan O'Brien; Guillermo Garcia-Manero; Srdan Verstovsek; Fabio P S Santos; Jianqin Shan; Mark Brandt; Marcos de Lima; Sherry Pierce; Hagop Kantarjian
Journal:  Blood       Date:  2010-10-05       Impact factor: 22.113

3.  Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy.

Authors:  Alexander E Perl; Margaret T Kasner; Doris Shank; Selina M Luger; Martin Carroll
Journal:  Clin Cancer Res       Date:  2011-12-13       Impact factor: 12.531

4.  Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.

Authors:  Roland B Walter; Frederick R Appelbaum; Martin S Tallman; Noel S Weiss; Richard A Larson; Elihu H Estey
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

5.  Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.

Authors:  Mark Levis; Farhad Ravandi; Eunice S Wang; Maria R Baer; Alexander Perl; Steven Coutre; Harry Erba; Robert K Stuart; Michele Baccarani; Larry D Cripe; Martin S Tallman; Giovanna Meloni; Lucy A Godley; Amelia A Langston; Sergio Amadori; Ian D Lewis; Arnon Nagler; Richard Stone; Karen Yee; Anjali Advani; Dan Douer; W Wiktor-Jedrzejczak; Gunnar Juliusson; Mark R Litzow; Stephen Petersdorf; Miguel Sanz; Hagop M Kantarjian; Takashi Sato; Lothar Tremmel; Debra M Bensen-Kennedy; Donald Small; B Douglas Smith
Journal:  Blood       Date:  2011-01-26       Impact factor: 22.113

6.  Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia.

Authors:  Marina Y Konopleva; Roland B Walter; Stefan H Faderl; Elias J Jabbour; Zhihong Zeng; Gautam Borthakur; Xuelin Huang; Tapan M Kadia; Peter P Ruvolo; Jennie B Feliu; Hongbo Lu; Lakiesha Debose; Jan A Burger; Michael Andreeff; Wenbin Liu; Keith A Baggerly; Steven M Kornblau; L Austin Doyle; Elihu H Estey; Hagop M Kantarjian
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

Review 7.  Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature.

Authors:  Kelly J Norsworthy; Amy E DeZern; Hua-Ling Tsai; Wesley A Hand; Ravi Varadhan; Steven D Gore; Ivana Gojo; Keith Pratz; Hetty E Carraway; Margaret Showel; Michael A McDevitt; Douglas Gladstone; Gabriel Ghiaur; Gabrielle Prince; Amy H Seung; Dina Benani; Mark J Levis; Judith E Karp; B Douglas Smith
Journal:  Leuk Res       Date:  2017-08-30       Impact factor: 3.156

8.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316

9.  High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML.

Authors:  Sanjay S Patel; Frank C Kuo; Christopher J Gibson; David P Steensma; Robert J Soiffer; Edwin P Alyea; Yi-Bin A Chen; Amir T Fathi; Timothy A Graubert; Andrew M Brunner; Martha Wadleigh; Richard M Stone; Daniel J DeAngelo; Valentina Nardi; Robert P Hasserjian; Olga K Weinberg
Journal:  Blood       Date:  2018-05-03       Impact factor: 22.113

10.  International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis.

Authors:  Jason Gotlib; Animesh Pardanani; Cem Akin; Andreas Reiter; Tracy George; Olivier Hermine; Hanneke Kluin-Nelemans; Karin Hartmann; Wolfgang R Sperr; Knut Brockow; Lawrence B Schwartz; Alberto Orfao; Daniel J Deangelo; Michel Arock; Karl Sotlar; Hans-Peter Horny; Dean D Metcalfe; Luis Escribano; Srdan Verstovsek; Ayalew Tefferi; Peter Valent
Journal:  Blood       Date:  2013-01-16       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.